UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Benefit of adjuvant trastuzumab-based chemotherapy in T1ab node-negative HER2-overexpressing breast carcinomas: a multicenter retrospective series

Annals of oncology, 2013-04, Vol.24 (4), p.916-924

2013

Volltextzugriff (PDF)

Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs)

Oncoimmunology, 2023-12, Vol.12 (1), p.2204754-2204754

2023

Volltextzugriff (PDF)

Nivolumab in patients with advanced renal cell carcinoma in France: interim results of the observational, real-world WITNESS study

ESMO open, 2024-07, Vol.9 (7), p.103602, Article 103602

2024

Volltextzugriff (PDF)

Variation in neutrophil to lymphocyte ratio (NLR) as predictor of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (mNSCLC) patients treated with nivolumab

Cancer Immunology, Immunotherapy, 2020-12, Vol.69 (12), p.2513-2522

2020

Volltextzugriff (PDF)

Quelle stratégie thérapeutique pour les stades métastatiques ?

Oncologie (Paris, France), 2018-07, Vol.20 (7-12), p.211-219

2018

Volltextzugriff (PDF)

Lien épidémiologique entre comportement alimentaire et cancer: exemple du cancer colorectal

Bulletin du cancer, 2009-06, Vol.96 (6), p.647-658

2009

Volltextzugriff (PDF)

Elderly patients (pts) with advanced Renal Cell Carcinoma (aRCC) treated with Nivolumab (N): A subgroup analysis from the WITNESS real-world study in France

European urology open science (Online), 2020-11, Vol.21, p.S182

2020

Volltextzugriff (PDF)

IO-Synthesise RCC: A pooled analysis of real-world outcomes for advanced renal cell carcinoma patients treated with nivolumab in France and Germany

European urology open science (Online), 2020-11, Vol.21, p.S180-S181

2020

Volltextzugriff (PDF)

Epidemiological link between eating habits and cancer: the example of colorectal cancer

Bulletin du cancer, 2009-06, Vol.96 (6), p.647

2009

Volltextzugriff (PDF)

1700P Impact of sarcomatoid (S) and rhabdoid (R) components (comp.) on the efficacy of nivolumab (N) +/- ipilimumab (I) in the first-line (L1) treatment of metastatic clear cell renal cell carcinoma (mRCC) in the randomized phase II BIONIKK trial

Annals of oncology, 2024-09, Vol.35, p.S1019-S1019

2024

Volltextzugriff (PDF)

1710P Exposure-response (E/R) relationship of nivolumab (N) and ipilimumab (I) in patients (pts) with metastatic renal cell clear cell carcinoma (mRCC) from the randomised phase II BIONIKK study

Annals of oncology, 2024-09, Vol.35, p.S1025-S1025

2024

Volltextzugriff (PDF)

A phase 2 BIOmarker driven trial with Nivolumab and Ipilimumab or VEGFR tKi in naïve metastatic Kidney cancer: the BIONIKK trial

Annals of oncology, 2017-09, Vol.28, p.v327-v327

2017

Volltextzugriff (PDF)

1460P IO-Synthesise RCC: Analysis of real-world (RW) health-related quality of life (HRQoL) outcomes with nivolumab for previously treated metastatic renal cell carcinoma (mRCC) using pooled data from France and Germany

Annals of oncology, 2022-09, Vol.33, p.S1212-S1213

2022

Volltextzugriff (PDF)

1468P IO-synthesise RCC: Real-world outcomes of nivolumab in patients (pts) with previously treated advanced non-clear cell renal cell carcinoma (nccRCC) – A pooled analysis from France and Germany

Annals of oncology, 2022-09, Vol.33, p.S1217-S1218

2022

Volltextzugriff (PDF)

1451MO In-situ immune markers predict nivolumab (N) +/-ipilimumab (I) efficacy in frontline metastatic clear cell renal cell carcinoma (mccRCC): Key ancillary analyses from the BIONIKK randomized trial

Annals of oncology, 2022-09, Vol.33, p.S1207

2022

Volltextzugriff (PDF)

1461P Impact of first-line (1L) therapy on outcomes of adult patients (pts) with metastatic MiT family translocation renal cell carcinomas (TRCC) treated in the contemporary immune checkpoint therapy (ICT) era

Annals of oncology, 2022-09, Vol.33, p.S1213-S1214

2022

Volltextzugriff (PDF)

Alimentation et cancer: quelles évidences, quelles recommandations ?

Oncologie (Paris, France), 2009-04, Vol.11 (4), p.191-199

2009

Volltextzugriff (PDF)

Phase I/II dose-finding, safety and efficacy study of radium-223 dichloride in renal cell carcinoma patients with bone metastases

Annals of oncology, 2016-10, Vol.27, p.vi295-vi295

2016

Volltextzugriff (PDF)

Thérapies ciblées et biomarqueurs compagnons dans les cancers de la prostate métastatiques

Médecine nucléaire : imagerie fonctionelle et métabolique, 2014-02, Vol.38 (1), p.31-37

2014

Volltextzugriff (PDF)

Alimentation et cancer : quelles évidences, quelles recommandations ? : Nutrition et cancer

Oncologie (Paris, France), 2009, Vol.11 (4), p.191-199

2009

Volltextzugriff (PDF)

Demonstration of reduced neoclassical energy transport in Wendelstein 7-X

Nature (London), 2021-08, Vol.596 (7871), p.221-226

2021

Volltextzugriff (PDF)

Survey of Graph Database Performance on the HPC Scalable Graph Analysis Benchmark

Web-Age Information Management, p.37-48

Volltextzugriff (PDF)

Position Statement of the Spanish Academy of Dermatology and Venereology on Teledermatology

Actas dermo-sifiliográficas (English ed.), 2018-01, Vol.109 (1), p.4-5

2018

Volltextzugriff (PDF)

1 – 23 von 23

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(23)
Mit Volltextzugriff
(19)

Publikationsform

Artikel
(22)
Tagungsberichte
(1)

Sprache

Englisch
(17)
Französisch
(6)

Erscheinungsjahr

n.n

Thema

Science & Technology
(7)
Humans
(6)
Oncology
(6)
Life Sciences & Biomedicine
(5)
Aged
(3)
Female
(3)
Middle Aged
(3)
Retrospective Studies
(3)
Adult
(2)
Aged, 80 And Over
(2)
Carcinoma, Renal Cell - Drug Therapy
(2)
Carcinoma, Renal Cell - Mortality
(2)
Immunology
(2)
Kidney Cancer
(2)
Kidney Neoplasms - Drug Therapy
(2)
Kidney Neoplasms - Mortality
(2)
Lung Neoplasms - Drug Therapy
(2)
Male
(2)
Medicine
(2)
Medicine & Public Health
(2)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Benefit of adjuvant trastuzumab-based chemotherapy in T1ab node-negative HER2-overexpressing breast carcinomas: a multicenter retrospective series

Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs)

Nivolumab in patients with advanced renal cell carcinoma in France: interim results of the observational, real-world WITNESS study

Variation in neutrophil to lymphocyte ratio (NLR) as predictor of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (mNSCLC) patients treated with nivolumab

Quelle stratégie thérapeutique pour les stades métastatiques ?

Lien épidémiologique entre comportement alimentaire et cancer: exemple du cancer colorectal

Elderly patients (pts) with advanced Renal Cell Carcinoma (aRCC) treated with Nivolumab (N): A subgroup analysis from the WITNESS real-world study in France

IO-Synthesise RCC: A pooled analysis of real-world outcomes for advanced renal cell carcinoma patients treated with nivolumab in France and Germany

Epidemiological link between eating habits and cancer: the example of colorectal cancer

1700P Impact of sarcomatoid (S) and rhabdoid (R) components (comp.) on the efficacy of nivolumab (N) +/- ipilimumab (I) in the first-line (L1) treatment of metastatic clear cell renal cell carcinoma (mRCC) in the randomized phase II BIONIKK trial

1710P Exposure-response (E/R) relationship of nivolumab (N) and ipilimumab (I) in patients (pts) with metastatic renal cell clear cell carcinoma (mRCC) from the randomised phase II BIONIKK study

A phase 2 BIOmarker driven trial with Nivolumab and Ipilimumab or VEGFR tKi in naïve metastatic Kidney cancer: the BIONIKK trial

1460P IO-Synthesise RCC: Analysis of real-world (RW) health-related quality of life (HRQoL) outcomes with nivolumab for previously treated metastatic renal cell carcinoma (mRCC) using pooled data from France and Germany

1468P IO-synthesise RCC: Real-world outcomes of nivolumab in patients (pts) with previously treated advanced non-clear cell renal cell carcinoma (nccRCC) – A pooled analysis from France and Germany

1451MO In-situ immune markers predict nivolumab (N) +/-ipilimumab (I) efficacy in frontline metastatic clear cell renal cell carcinoma (mccRCC): Key ancillary analyses from the BIONIKK randomized trial

1461P Impact of first-line (1L) therapy on outcomes of adult patients (pts) with metastatic MiT family translocation renal cell carcinomas (TRCC) treated in the contemporary immune checkpoint therapy (ICT) era

Alimentation et cancer: quelles évidences, quelles recommandations ?

Phase I/II dose-finding, safety and efficacy study of radium-223 dichloride in renal cell carcinoma patients with bone metastases

Thérapies ciblées et biomarqueurs compagnons dans les cancers de la prostate métastatiques

Alimentation et cancer : quelles évidences, quelles recommandations ? : Nutrition et cancer

Demonstration of reduced neoclassical energy transport in Wendelstein 7-X

Survey of Graph Database Performance on the HPC Scalable Graph Analysis Benchmark

Position Statement of the Spanish Academy of Dermatology and Venereology on Teledermatology

Suchergebnisse filtern